CN117696017B - Blood purification adsorption modified material and preparation method thereof - Google Patents
Blood purification adsorption modified material and preparation method thereof Download PDFInfo
- Publication number
- CN117696017B CN117696017B CN202410165242.XA CN202410165242A CN117696017B CN 117696017 B CN117696017 B CN 117696017B CN 202410165242 A CN202410165242 A CN 202410165242A CN 117696017 B CN117696017 B CN 117696017B
- Authority
- CN
- China
- Prior art keywords
- blood purification
- adsorption
- solution
- reaction
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001179 sorption measurement Methods 0.000 title claims abstract description 77
- 239000000463 material Substances 0.000 title claims abstract description 69
- 210000004369 blood Anatomy 0.000 title claims abstract description 68
- 239000008280 blood Substances 0.000 title claims abstract description 68
- 238000000746 purification Methods 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000006243 chemical reaction Methods 0.000 claims abstract description 37
- 239000007987 MES buffer Substances 0.000 claims abstract description 24
- 239000003054 catalyst Substances 0.000 claims abstract description 22
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000007800 oxidant agent Substances 0.000 claims abstract description 11
- 238000004140 cleaning Methods 0.000 claims abstract description 10
- 230000001590 oxidative effect Effects 0.000 claims abstract description 9
- 230000021523 carboxylation Effects 0.000 claims abstract description 7
- 238000006473 carboxylation reaction Methods 0.000 claims abstract description 7
- 238000002791 soaking Methods 0.000 claims abstract description 7
- 150000001412 amines Chemical class 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 4
- 239000003463 adsorbent Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 23
- -1 polyoxymethylene Polymers 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000002840 nitric oxide donor Substances 0.000 claims description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000004695 Polyether sulfone Substances 0.000 claims description 10
- 229920006393 polyether sulfone Polymers 0.000 claims description 10
- 239000012286 potassium permanganate Substances 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 229920006324 polyoxymethylene Polymers 0.000 claims description 8
- 230000035484 reaction time Effects 0.000 claims description 8
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 7
- 239000004743 Polypropylene Substances 0.000 claims description 7
- 239000004793 Polystyrene Substances 0.000 claims description 7
- 238000000354 decomposition reaction Methods 0.000 claims description 7
- 229910017604 nitric acid Inorganic materials 0.000 claims description 7
- 229920001155 polypropylene Polymers 0.000 claims description 7
- 229920002223 polystyrene Polymers 0.000 claims description 7
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 6
- 229950010033 ebselen Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- MPMSMUBQXQALQI-UHFFFAOYSA-N cobalt phthalocyanine Chemical compound [Co+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 MPMSMUBQXQALQI-UHFFFAOYSA-N 0.000 claims description 5
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- ADXNPXDFKKWVGE-UHFFFAOYSA-N n,n-dimethyltridecan-1-amine Chemical compound CCCCCCCCCCCCCN(C)C ADXNPXDFKKWVGE-UHFFFAOYSA-N 0.000 claims description 3
- 229920000768 polyamine Polymers 0.000 claims description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 claims description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 claims description 2
- KMHSUNDEGHRBNV-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=C(C#N)C(Cl)=N1 KMHSUNDEGHRBNV-UHFFFAOYSA-N 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 229910021389 graphene Inorganic materials 0.000 claims description 2
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 claims description 2
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 claims description 2
- 229940055619 selenocysteine Drugs 0.000 claims description 2
- 235000016491 selenocysteine Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000003929 acidic solution Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 239000002158 endotoxin Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 24
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 230000001951 hemoperfusion Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- JFPZQQZFBOOXGD-FHAQVOQBSA-N C(C)O.N[C@@H]([C@@H](C)CC)C(=O)O Chemical compound C(C)O.N[C@@H]([C@@H](C)CC)C(=O)O JFPZQQZFBOOXGD-FHAQVOQBSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BWBWXQDUYGOAIU-UHFFFAOYSA-N dodecan-1-amine;ethanol Chemical compound CCO.CCCCCCCCCCCCN BWBWXQDUYGOAIU-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- BJAARRARQJZURR-UHFFFAOYSA-N trimethylazanium;hydroxide Chemical compound O.CN(C)C BJAARRARQJZURR-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
The invention belongs to the field of blood purification materials, and particularly relates to a blood purification adsorption modified material and a preparation method thereof. The preparation method comprises the following steps: soaking the blood purification and adsorption material in an oxidant acid solution, and performing reaction and cleaning to obtain a carboxylation purification and adsorption material; EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylation purification adsorption material for reaction, then amine-containing hydrophobic compound-ethanol/water solution is added for reaction, finally NO catalyst solution is added for reaction, and after completion, the blood purification adsorption modified material is obtained through cleaning and drying. According to the invention, the hydrophobic compound and the NO catalyst are modified on the surface of the blood purification adsorption material, so that the biocompatibility of the adsorption material can be effectively ensured, and the coagulation and inflammatory reaction can be reduced; also improves the removal of non-polar harmful substances, fat-soluble drugs, fat-soluble substances, non-polar bacterial endotoxins and harmful proteins which can coordinate with NO catalysts.
Description
Technical Field
The invention belongs to the field of blood purification materials, and particularly relates to a blood purification adsorption modified material and a preparation method thereof.
Background
Blood purification therapy is an extracorporeal circulation type life support technology, and has been used clinically for treating various diseases such as poisoning (drugs, pesticides, heavy metals, biotoxins, drugs, etc.), uremia, liver diseases, hyperlipidemia, septicemia, autoimmune diseases, etc. Patients with these diseases accumulate large amounts of exogenous or endogenous toxins in the body either by ingestion of toxic substances or by dysfunction of their own detoxification, immune, metabolic systems. Under the condition that the function of the detoxification organs (kidneys and livers) of the patient is invalid, the blood purification therapy can lead the blood of the patient out of the body and pass through the purification device to purify and remove toxins in the blood, and the purified blood is returned to the body of the patient, so that the detoxification system of the patient is replaced to remove the toxins. The blood purification modes include: hemodialysis, hemofiltration and hemodiafiltration. The core purification material for blood perfusion is a blood perfusion adsorbent, and toxins in blood are removed through broad-spectrum adsorption and specific adsorption of the adsorbent based on an adsorption principle. The broad-spectrum adsorbent plays an important role in the process, and can simultaneously remove various harmful substances including but not limited to urinary toxins, creatinine, bilirubin, endotoxin, inflammatory factors, drug residues, toxins and the like, shorten the treatment time and times, and lighten the organ burden, thereby reducing the pain and the economic pressure of patients.
Although widely used in clinic, broad spectrum adsorption columns still face a number of difficulties and challenges during use. Comprising the following steps: 1) Equilibrium of selectivity and affinity: broad spectrum adsorbents require high adsorption capacity for a variety of substances, but at the same time do not wish to produce excessive adsorption of normal blood components (e.g., proteins, electrolytes, nutrients, etc.). Thus, it is a significant challenge to design and produce a broad-spectrum adsorbent having both high selectivity and high affinity. 2) Biocompatibility: the adsorbent needs to be in direct contact with blood and thus must have good biocompatibility to avoid adverse reactions such as thrombus, inflammation or immune response. Currently, many adsorbents have not achieved the desired biocompatibility. 3) Easy blockage: blood contains various solid components such as red blood cells, white blood cells, platelets, fibrin, etc., which may clog the pores of the adsorbent, thereby affecting its adsorption effect and perfusion efficiency. 4) Broad spectrum performance: the harmful substances in blood are various, including organic substances, inorganic substances, drugs, toxins, pathogens, cells, etc. It is a great challenge to develop an adsorbent that has efficient adsorption properties for these various substances. 5) Adsorption of proteins: blood contains a large amount of proteins, and some adsorbents may have nonspecific adsorption of proteins, thereby changing the composition and properties of blood.
In blood perfusion, the broad-spectrum adsorption of the adsorbent mainly comprises van der Waals force, hydrogen bonding force, electrostatic force, hydrophobic effect, coordination effect and the like. Therefore, the surface modification technology enables the broad-spectrum adsorbent to have various acting forces, and is an effective means for realizing efficient adsorption of various substances.
Therefore, the technical scheme of the invention is provided based on the above.
Disclosure of Invention
In order to solve the problems in the prior art, the scheme of the invention is to provide a preparation method of a blood purification adsorption modified material, which comprises the following steps:
(1) Soaking the blood purification and adsorption material in an oxidant acid solution, and performing reaction and cleaning to obtain a carboxylation purification and adsorption material;
(2) EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylation purification adsorption material for reaction, then amine-containing hydrophobic compound-ethanol/water solution is added for reaction, finally NO catalyst solution is added for reaction, and after completion, the blood purification adsorption modified material is obtained through cleaning and drying.
To facilitate understanding of the present invention, the reaction process of the present invention will be described:
Firstly, generating carboxyl on the surface of a blood purification adsorption material by utilizing the oxidation action of an oxidant; and then under the action of carboxyl activator EDC/NHS, the hydrophobic compound is combined with carboxyl on the surface of the adsorption material and a catalyst capable of catalyzing NO donor to decompose and release NO respectively through amide reaction and chelation, and the hydrophobic compound and the catalyst capable of catalyzing NO donor to decompose and release NO are efficiently and firmly fixed on the surface of the adsorption column material through a chemical grafting mode. The hydrophobicity of the surface of the blood purification and adsorption modified material is increased, so that the adsorption capacity of the blood purification process to toxins and wastes is improved; the catalyst capable of catalyzing the decomposition of the NO donor to release NO can catalyze the endogenous NO donor in blood to continuously release NO, so that the biocompatibility of the blood purification and adsorption modified material is ensured. The catalysis synergistic effect of the hydrophobic compound and the catalyst for decomposing NO donor to release NO improves the adsorption performance of the blood purification adsorption modified material. The invention can be applied to the surface modification treatment of blood purification materials and instruments.
Wherein, CAS number of NHS is: 6066-82-6, the English name is: N-Hydroxysuccinimide, chinese name: n-hydroxysuccinimide.
The CAS number of EDC is: 25952-53-8, english name:
1- (3-Dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, the Chinese name is: 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride.
The CAS number for MES is: 4432-31-9, chinese name: 2-morpholinoethanesulfonic acid.
Preferably, in the step (1), the blood purification adsorption material is one of activated carbon resin, cation exchange resin, anion exchange resin, polystyrene, polyoxymethylene, polypropylene, polysulfone, polyethersulfone, nano activated carbon, nano graphene, and agarose.
Preferably, in step (1), the oxidant acid solution is prepared by mixing an oxidant and an acidic aqueous solution;
And/or the oxidant is one or the combination of more than two of nitric acid, potassium permanganate and hydrogen peroxide; the concentration of the nitric acid and the hydrogen peroxide is 0.5-15%, and the concentration of the potassium permanganate is 0.5-5 mg/mL;
and/or the pH value of the acidic aqueous solution is 3-6.5.
Preferably, in the step (1), the reaction temperature is 10-40 ℃ and the reaction time is 1-48 h.
Preferably, in the step (2), the EDC/NHS-MES buffer is prepared by mixing EDC/NHS and MES buffer;
And/or the amino-containing hydrophobic compound-ethanol/water solution is prepared by mixing the amino-containing hydrophobic compound and the ethanol/water solution;
And/or the NO catalyst solution is prepared by mixing a catalyst for catalyzing the decomposition of a NO donor to release NO with water.
Preferably, the pH of the MES buffer solution is 3-6.5;
and/or EDC/NHS-MES buffer solution, wherein the concentration of EDC is 0.75-7.5 mmol/L, and the concentration of NHS is 0.5-5 mmol/L;
And/or the amino-containing hydrophobic compound is one or more than two of hexadecylamine, dodecylamine, N-palmitoylethanolamine, N-oleoylethanolamide, leucine, isoleucine, phenylalanine, polydimethylsiloxane amine, dodecyltrimethylamine, fluorododecylamine, fluorinated polyamine and poly-p-aminophenether;
And/or, in the amino-containing hydrophobic compound-ethanol/water solution, the concentration of the amino-containing hydrophobic compound is 0.1-10 mg/mL;
and/or the catalyst for catalyzing the decomposition of the NO donor to release NO is one or a combination of more than two of Cu 2+、Fe2+、Fe3+、Mn2+、Co2+、Ag+, ascorbic acid, iron phthalocyanine, cobalt phthalocyanine, ebselen and selenocysteine;
and/or the concentration of the catalyst for catalyzing the decomposition of the NO donor to release NO in the NO catalyst solution is 0.1-10 mg/mL.
Preferably, in the step (2), the reaction temperature is 10-40 ℃ and the reaction time is 1-48 h.
Based on the same technical concept, a further aspect of the present invention is to provide a blood purification and adsorption modified material obtained by the above preparation method.
The beneficial effects of the invention are as follows:
1. According to the preparation method, carboxyl is generated on the surface of the hemoperfusion adsorbent in situ by utilizing the oxidization of the oxidant in an acidic aqueous solution, so that the inert surface is converted into an active surface. The carboxylation surface process has no material dependence, can fully oxidize the surface of the adsorbent and generate carboxyl, does not have adverse effect on the adsorbent material, and has wide applicability and safety.
2. The carboxylated adsorbent and the hydrophobic compound containing amino react in amide, and the hydrophobic compound molecules are fixed on the surface of the material in a chemical bonding mode, so that the hydrophobicity of the adsorbent material is obviously improved, and the pore size of an adsorption column is not influenced.
3. When the NO catalyst chemically immobilized on the surface of the adsorbent contacts with blood, NO donors in the blood are catalyzed to decompose and release NO, and the NO is taken as a vascular signal molecule, so that activation and aggregation of blood platelets can be effectively inhibited, thereby reducing the formation of thrombus on the surface of the adsorbent and improving the blood compatibility; meanwhile, NO can inhibit the adhesion and migration of white blood cells, inhibit the release of inflammatory cytokines (such as TNF-alpha, IL-1 and IL-6) and chemokines (such as MCP-1), and has excellent anti-inflammatory effect. The excellent blood compatibility and anti-inflammatory effect can further improve the biocompatibility of the adsorbent, reduce the blocking rate of the pores of the adsorbent, and improve the adsorption effect and the perfusion efficiency of the adsorbent.
4. The modified adsorbent and the adsorbate have various acting forces, including comprehensive performance of the adsorbent material, hydrophobic effect, coordination effect of the NO catalyst, van der Waals force, hydrogen bond and electrostatic acting force, and two or more of the various acting forces can cooperatively realize efficient adsorption of various harmful substances in blood.
5. The method has the advantages of simple operation, high efficiency in reaction, NO need of expensive equipment, broad-spectrum practicability, and capability of fixing different hydrophobic compounds and NO catalysts on the surface of the adsorbent to prepare the blood purification adsorption column with excellent adsorption performance.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, it being obvious that the drawings in the following description are only some embodiments of the invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a graph of water contact angle before/after modification of polystyrene as described in example 1.
FIG. 2 shows the creatinine (a) and urea nitrogen (b) contents of blood reacted with blood of an acute kidney injury rabbit before/after modification of the polyoxymethylene adsorption column material described in example 2.
FIG. 3 is an SEM topography (b) of the polyethersulfone hemoperfusion adsorption column and microspheres (a) described in example 3, the polyethersulfone microspheres before/after modification reacting with platelet rich plasma.
FIG. 4 shows XPS full spectrum (a) of the back surface of the modified polypropylene and high resolution spectrum (b) of Se element as described in example 4, and the rate (c) of NO release by the catalytic NO donor.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, based on the examples herein, which are within the scope of the invention as defined by the claims, will be within the scope of the invention as defined by the claims.
Example 1
The embodiment provides a preparation method of a blood purification adsorption modified material, which comprises the following steps:
(1) Mixing hydrogen peroxide with an acidic aqueous solution having a ph=6 to obtain an aqueous hydrogen peroxide solution having a concentration of 5%;
(2) Mixing EDC/NHS with MES buffer solution with pH=5 to obtain EDC/NHS-MES buffer solution; wherein, the concentration of EDC is 1mmol/L, and the concentration of NHS is 1.5mmol/L;
(3) Mixing dodecylamine with ethanol/water solution to obtain dodecylamine-ethanol/water solution with concentration of 2 mg/mL; wherein, in the ethanol/water solution, the volume ratio of ethanol to water is 4:1;
(4) Copper chloride is mixed with water to obtain a copper chloride solution with the concentration of 1 mg/mL;
(5) Fully soaking the polystyrene serving as a blood purification adsorption material in a 5% hydrogen peroxide aqueous solution, reacting for 2 hours at 20 ℃, and then cleaning to obtain a carboxylated polystyrene purification adsorption material;
(6) EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylated polystyrene purification adsorption material for reaction, dodecylamine-ethanol/water solution is then added for reaction, copper chloride solution is finally added for reaction, and after the reaction is completed, the purification adsorption modified material for blood is obtained by cleaning and drying; the reaction was carried out at 20℃for a total reaction time of 5h.
Example 2
The embodiment provides a preparation method of a blood purification adsorption modified material, which comprises the following steps:
(1) Mixing nitric acid with an acidic aqueous solution with ph=3 to obtain an aqueous nitric acid solution with a concentration of 1%;
(2) Mixing EDC/NHS with MES buffer solution with pH=3 to obtain EDC/NHS-MES buffer solution; wherein, the concentration of EDC is 0.75mmol/L, and the concentration of NHS is 0.5mmol/L;
(3) Mixing isoleucine with ethanol/water solution to obtain isoleucine-ethanol/water solution with concentration of 0.1 mg/mL; wherein, in the ethanol/water solution, the volume ratio of ethanol to water is 4:1;
(4) Mixing ascorbic acid with water to obtain ascorbic acid solution with concentration of 0.1 mg/mL;
(5) Fully soaking the blood purification adsorption material polyformaldehyde in 1% nitric acid aqueous solution, reacting for 12 hours at 10 ℃, and then cleaning to obtain carboxylated polyformaldehyde purification adsorption material;
(6) EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylated polyformaldehyde purification adsorption material for reaction, isoleucine-ethanol/water solution is then added for reaction, and finally ascorbic acid solution is added for reaction, and after completion, the blood purification adsorption modified material is obtained by washing and drying; the reaction was carried out at 10℃for a total reaction time of 12h.
Example 3
The embodiment provides a preparation method of a blood purification adsorption modified material, which comprises the following steps:
(1) Mixing potassium permanganate with an acidic aqueous solution with ph=6.5 to obtain a potassium permanganate aqueous solution with a concentration of 5 mg/mL;
(2) Mixing EDC/NHS with MES buffer with pH=6.5 to obtain EDC/NHS-MES buffer; wherein, the concentration of EDC is 7.5mmol/L, and the concentration of NHS is 5mmol/L;
(3) Mixing dodecyl trimethylamine with ethanol/water solution to obtain dodecyl trimethylamine-ethanol/water solution with the concentration of 10 mg/mL; wherein, in the ethanol/water solution, the volume ratio of ethanol to water is 4:1;
(4) Mixing cobalt phthalocyanine with water to obtain a cobalt phthalocyanine solution with the concentration of 10 mg/mL;
(5) Fully soaking the blood purification adsorption material polyethersulfone in 5mg/mL potassium permanganate aqueous solution, reacting for 1h at 40 ℃, and then cleaning to obtain carboxylated polyethersulfone purification adsorption material;
(6) EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylated polyether sulfone purification and adsorption material for reaction, dodecyl trimethylamine-ethanol/water solution is then added for reaction, cobalt phthalocyanine solution is finally added for reaction, and after the reaction is completed, the material is washed and dried to obtain the blood purification and adsorption modified material; the reaction was carried out at 40℃for a total reaction time of 1h.
Example 4
The embodiment provides a preparation method of a blood purification adsorption modified material, which comprises the following steps:
(1) Mixing potassium permanganate with an acidic aqueous solution with ph=6.5 to obtain a potassium permanganate aqueous solution with a concentration of 2 mg/mL;
(2) Mixing EDC/NHS with MES buffer with pH=6.5 to obtain EDC/NHS-MES buffer; wherein, the concentration of EDC is 7.5mmol/L, and the concentration of NHS is 5mmol/L;
(3) Mixing the fluorinated polyamine with an ethanol/water solution to obtain a fluorinated polyamine-ethanol/water solution with a concentration of 10 mg/mL; wherein, in the ethanol/water solution, the volume ratio of ethanol to water is 4:1;
(4) Mixing ebselen with water to obtain ebselen solution with concentration of 5 mg/mL;
(5) Fully soaking the blood purification adsorption material polypropylene in 1mg/mL potassium permanganate aqueous solution, reacting for 48 hours at 40 ℃, and then cleaning to obtain carboxylated polypropylene purification adsorption material;
(6) EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylated polypropylene purification adsorption material for reaction, then fluorinated polyamine-ethanol/water solution is added for reaction, and finally ebselen solution is added for reaction, and after completion, the material is washed and dried to obtain the blood purification adsorption modified material; the reaction was carried out at 40℃for a total reaction time of 48h.
Verification example
Fig. 1 is a graph of water contact angle before/after modification of polystyrene described in example 1, from which it can be seen that water contact on the surface of the adsorption column material is significantly improved after modification.
FIG. 2 shows the creatinine (a) and urea nitrogen (b) contents of blood reacted with blood of an acute kidney injury rabbit before/after modification of the polyoxymethylene adsorption column material described in example 2. The graph shows that the modified polyformaldehyde material can obviously reduce the contents of creatinine and urea nitrogen in blood, and the modified adsorption column has excellent adsorption performance on toxic substances in blood.
FIG. 3 is an SEM topography (b) of the polyethersulfone hemoperfusion adsorption column and microspheres (a) described in example 3, the polyethersulfone microspheres before/after modification reacting with platelet rich plasma. From the figure, it can be seen that the modified polyethersulfone still has excellent blood compatibility.
FIG. 4 shows XPS full spectrum (a) of the back surface of the modified polypropylene and high resolution spectrum (b) of Se element as described in example 4, and the rate (c) of NO release by the catalytic NO donor. From the figure, it can be found that ebselen which catalyzes the decomposition of the NO donor and releases NO is successfully modified to the surface of the material, and can catalyze the release of NO in the physiological concentration range.
The foregoing is merely illustrative of the present invention, and the present invention is not limited thereto, and any person skilled in the art will readily recognize that variations or substitutions are within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (7)
1. A method for preparing a blood purification adsorption modified material, which is characterized by comprising the following steps:
(1) Soaking the blood purification and adsorption material in an oxidant acid solution, and performing reaction and cleaning to obtain a carboxylation purification and adsorption material; wherein:
The blood purification adsorption material is one of activated carbon resin, cation exchange resin, anion exchange resin, polystyrene, polyoxymethylene, polypropylene, polysulfone, polyether sulfone, nano activated carbon, nano graphene and agarose;
(2) EDC/NHS-MES buffer solution is firstly added to the surface of the carboxylation purification adsorption material for reaction, then amine-containing hydrophobic compound-ethanol/water solution is added for reaction, finally NO catalyst solution is added for reaction, and after completion, the material is washed and dried, thus obtaining the blood purification adsorption modified material; wherein:
The NO catalyst solution is prepared by mixing a catalyst for catalyzing NO donor to decompose and release NO with water;
the catalyst for catalyzing the decomposition of the NO donor to release NO is one or a combination of more than two of Cu 2+、Fe2+、Fe3+、Mn2+、Co2+、Ag+, ascorbic acid, iron phthalocyanine, cobalt phthalocyanine, ebselen and selenocysteine;
In the NO catalyst solution, the concentration of a catalyst for catalyzing the decomposition of the NO donor to release NO is 0.1-10 mg/mL.
2. The method for producing a blood purification adsorption-modified material according to claim 1, wherein in the step (1), the oxidizing agent acidic solution is prepared by mixing an oxidizing agent and an acidic aqueous solution;
And/or the oxidant is one or the combination of more than two of nitric acid, potassium permanganate and hydrogen peroxide; the concentration of the nitric acid and the hydrogen peroxide is 0.5-15%, and the concentration of the potassium permanganate is 0.5-5 mg/mL;
and/or the pH value of the acidic aqueous solution is 3-6.5.
3. The method for producing a modified adsorbent for blood purification according to claim 1, wherein in the step (1), the reaction temperature is 10 to 40 ℃ and the reaction time is 1 to 48 hours.
4. The method for preparing a blood purification and adsorption modified material according to claim 1, wherein in the step (2), the EDC/NHS-MES buffer is prepared by mixing EDC/NHS and MES buffer;
and/or the amino-containing hydrophobic compound-ethanol/water solution is prepared by mixing the amino-containing hydrophobic compound and the ethanol/water solution.
5. The method for producing a modified adsorbent for blood purification according to claim 4, wherein the MES buffer has a pH of 3 to 6.5;
and/or EDC/NHS-MES buffer solution, wherein the concentration of EDC is 0.75-7.5 mmol/L, and the concentration of NHS is 0.5-5 mmol/L;
And/or the amino-containing hydrophobic compound is one or more than two of hexadecylamine, dodecylamine, N-palmitoylethanolamine, N-oleoylethanolamide, leucine, isoleucine, phenylalanine, polydimethylsiloxane amine, dodecyltrimethylamine, fluorododecylamine, fluorinated polyamine and poly-p-aminophenether;
and/or, in the amino-containing hydrophobic compound-ethanol/water solution, the concentration of the amino-containing hydrophobic compound is 0.1-10 mg/mL.
6. The method for producing a modified adsorbent for blood purification according to claim 1, wherein in the step (2), the reaction temperature is 10 to 40 ℃ and the reaction time is 1 to 48 hours.
7. The modified blood purification and adsorption material obtained by the method according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410165242.XA CN117696017B (en) | 2024-02-05 | 2024-02-05 | Blood purification adsorption modified material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410165242.XA CN117696017B (en) | 2024-02-05 | 2024-02-05 | Blood purification adsorption modified material and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117696017A CN117696017A (en) | 2024-03-15 |
| CN117696017B true CN117696017B (en) | 2024-05-07 |
Family
ID=90144660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410165242.XA Active CN117696017B (en) | 2024-02-05 | 2024-02-05 | Blood purification adsorption modified material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117696017B (en) |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035660A1 (en) * | 1996-03-23 | 1997-10-02 | White Eagle International Technologies Group, Inc. | Sorbents for removing toxicants from blood or plasma, and method of producing same |
| CN1431044A (en) * | 2003-01-20 | 2003-07-23 | 浙江大学 | Adsorbent based on montmorillonite for purifying blood and its preparing method |
| JP2003284774A (en) * | 2002-03-28 | 2003-10-07 | Toray Ind Inc | Material for improving function of respiratory organ |
| CN1665554A (en) * | 2002-05-09 | 2005-09-07 | 汉莫堤克科技公司 | Compounds and method for coating surfaces in a haemocompatible manner |
| CN101024149A (en) * | 2007-01-12 | 2007-08-29 | 中国科学院上海有机化学研究所 | Blood plasma lipide component adsorbing separation polymer porous film material, its preparing and use |
| CN103230781A (en) * | 2013-05-03 | 2013-08-07 | 重庆大学 | Heparin-phenylalanine adsorption material for blood purification method for removing endotoxin |
| CN103800953A (en) * | 2014-01-20 | 2014-05-21 | 四川大学华西医院 | Device for preparing hemofiltration replacement fluid and application method thereof |
| CN105088783A (en) * | 2015-08-03 | 2015-11-25 | 佛山市博新生物科技有限公司 | Modification method for blood purification material |
| WO2016052567A1 (en) * | 2014-09-29 | 2016-04-07 | 旭化成メディカル株式会社 | Hollow fiber membrane-type blood purification device |
| CN107596474A (en) * | 2017-11-01 | 2018-01-19 | 桂林欣中伊健康产业有限公司 | Blood plasma degreasing purifying treatment method |
| WO2018139047A1 (en) * | 2017-01-30 | 2018-08-02 | 国立研究開発法人物質・材料研究機構 | Urea-adsorbing fibers, method of manufacturing same, blood purification filter using same, and blood purification apparatus using same |
| CN113797404A (en) * | 2021-01-06 | 2021-12-17 | 郝云玲 | Device for supplementing Nitric Oxide (NO) to blood |
| CN115490867A (en) * | 2022-10-11 | 2022-12-20 | 健帆生物科技集团股份有限公司 | Adsorption resin and preparation method and application thereof |
| CN116966756A (en) * | 2023-07-12 | 2023-10-31 | 天津市第三中心医院 | Blood purifying membrane for removing proinflammatory cytokines and preparation method thereof |
| CN117123198A (en) * | 2023-09-27 | 2023-11-28 | 佛山市博新生物科技有限公司 | Modification method of blood purification adsorption material |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10064406B2 (en) * | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
-
2024
- 2024-02-05 CN CN202410165242.XA patent/CN117696017B/en active Active
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997035660A1 (en) * | 1996-03-23 | 1997-10-02 | White Eagle International Technologies Group, Inc. | Sorbents for removing toxicants from blood or plasma, and method of producing same |
| JP2003284774A (en) * | 2002-03-28 | 2003-10-07 | Toray Ind Inc | Material for improving function of respiratory organ |
| CN1665554A (en) * | 2002-05-09 | 2005-09-07 | 汉莫堤克科技公司 | Compounds and method for coating surfaces in a haemocompatible manner |
| CN1431044A (en) * | 2003-01-20 | 2003-07-23 | 浙江大学 | Adsorbent based on montmorillonite for purifying blood and its preparing method |
| CN101024149A (en) * | 2007-01-12 | 2007-08-29 | 中国科学院上海有机化学研究所 | Blood plasma lipide component adsorbing separation polymer porous film material, its preparing and use |
| CN103230781A (en) * | 2013-05-03 | 2013-08-07 | 重庆大学 | Heparin-phenylalanine adsorption material for blood purification method for removing endotoxin |
| CN103800953A (en) * | 2014-01-20 | 2014-05-21 | 四川大学华西医院 | Device for preparing hemofiltration replacement fluid and application method thereof |
| WO2016052567A1 (en) * | 2014-09-29 | 2016-04-07 | 旭化成メディカル株式会社 | Hollow fiber membrane-type blood purification device |
| CN105088783A (en) * | 2015-08-03 | 2015-11-25 | 佛山市博新生物科技有限公司 | Modification method for blood purification material |
| WO2018139047A1 (en) * | 2017-01-30 | 2018-08-02 | 国立研究開発法人物質・材料研究機構 | Urea-adsorbing fibers, method of manufacturing same, blood purification filter using same, and blood purification apparatus using same |
| CN107596474A (en) * | 2017-11-01 | 2018-01-19 | 桂林欣中伊健康产业有限公司 | Blood plasma degreasing purifying treatment method |
| CN113797404A (en) * | 2021-01-06 | 2021-12-17 | 郝云玲 | Device for supplementing Nitric Oxide (NO) to blood |
| CN115490867A (en) * | 2022-10-11 | 2022-12-20 | 健帆生物科技集团股份有限公司 | Adsorption resin and preparation method and application thereof |
| CN116966756A (en) * | 2023-07-12 | 2023-10-31 | 天津市第三中心医院 | Blood purifying membrane for removing proinflammatory cytokines and preparation method thereof |
| CN117123198A (en) * | 2023-09-27 | 2023-11-28 | 佛山市博新生物科技有限公司 | Modification method of blood purification adsorption material |
Non-Patent Citations (4)
| Title |
|---|
| Absorptive capacity of iron-based magnetic carriers for blood detoxi"cation;Lubov Kh. Komissarova等;《Journal of Magnetism and Magnetic Materials》;20011231;第221卷(第1-2期);第197-201页 * |
| Preparation of Cu2+-loaded Porous Chitosan Particles for Immunoglobulin G Adsorption;Rong-Zheng Yue等;《Therapeutic Apheresis and Dialysis》;20080523;第12卷(第03期);第209-215页 * |
| 聚醚砜血液净化膜的研究进展;赵伟锋等;《高分子通报》;20171015(第10期);第80-88页 * |
| 血液净化类纳米材料的制备及其应用研究;王蒙;《中国优秀硕士学位论文全文数据库 (工程科技Ⅰ辑)》;20220315(第03期);B020-1328 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117696017A (en) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| van Gelder et al. | Urea removal strategies for dialysate regeneration in a wearable artificial kidney | |
| Cheah et al. | Nanoporous biomaterials for uremic toxin adsorption in artificial kidney systems: A review | |
| EP1446174B1 (en) | Device comprising layers for removing uremic toxins in dialysis processes and method of manufacture | |
| JP2004525747A (en) | Cartridge useful for washing dialysate | |
| Liu et al. | Alginate/HSA double-sided functional PVDF multifunctional composite membrane for bilirubin removal | |
| Winchester et al. | Sorbent hemoperfusion in end-stage renal disease: an in-depth review | |
| CN109692372B (en) | Five-layer blood perfusion device and blood perfusion method | |
| CN117696017B (en) | Blood purification adsorption modified material and preparation method thereof | |
| JPWO2004098680A1 (en) | Adsorbent and adsorber for low density lipoprotein and fibrinogen capable of whole blood treatment | |
| US4959148A (en) | Method and apparatus for specific affinity enhanced transport bioreactor | |
| Wang et al. | Bilirubin removal by polymeric adsorbents for hyperbilirubinemia therapy | |
| CN101322932B (en) | Water-soluble polymer adsorption material coupling cyclodextrin and uses thereof | |
| EP3887034B1 (en) | Method and composition for removing uremic toxins | |
| CN113426423B (en) | Adsorbent for removing LDL (low density lipoprotein) by extracorporeal blood circulation, preparation method thereof and perfusion device | |
| CN108097212B (en) | Preparation of high-strength three-dimensional graphene composite adsorbent and adsorption and catalytic degradation application thereof | |
| US5821193A (en) | Adsorbent having a terminal hydrazine group and a method for removing ketoamine-containing protein | |
| CN109174022B (en) | Method for immobilizing adsorption material for blood purification | |
| CN117563570B (en) | Resin for protein adsorption and preparation method thereof | |
| CN114405488B (en) | Protein-bound toxoid blood perfusion adsorbent and preparation method and application thereof | |
| JP2007151612A (en) | Carbonyl compound eliminating material for processing carbohydrate solution | |
| RU2161987C2 (en) | Method of modification of carbon sorbent | |
| JPH0975725A (en) | Bradykinin adsorbent, adsorbing and removing method and adsorber | |
| CN114540332A (en) | Preparation method and application of uricase immobilized resin | |
| JPH05285381A (en) | Low-specific gravity lipoprotein adsorptive material | |
| JP4141224B2 (en) | Low density lipoprotein and fibrinogen adsorbent and adsorber thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |